Skip to main content
    I

    Insight Molecular Diagnostics Inc. (IMDX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $1.86
    -0.28 (-13.08%)

    Market Cap: $70.03M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insight Molecular Diagnostics Inc. (IMDX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Insight Molecular Diagnostics are Precipio (PRPO), Exagen (XGN) and Cardiff Oncology (CRDF). By market cap, Insight Molecular Diagnostics ranks 8th of the 13 companies on this page; CareDx (CDNA) is the largest at $4.09B.

    Peer Comparison

    IMDX's ROIC of 197.8% is above the peer median of -23.3%, and its revenue growth of -53.9% is below the median of 7.6%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Insight Molecular Diagnostics (IMDX)$70.03MN/A40.9x0.0%197.8%-53.9%0.00%
    Precipio Inc (PRPO)$39.68MN/A1.3x-4.1%-5.7%8.3%0.00%
    Exagen Inc (XGN)$105.37MN/A1.3x-25.1%-40.4%6.8%0.00%
    Cardiff Oncology Inc (CRDF)$56.49MN/A115.5x0.0%N/A-14.1%0.00%
    Oncolytics Biotech Inc (ONCY)$48.51MN/AN/A0.0%N/A0.0%0.00%
    Champions Oncology Inc (CSBR)$65.49MN/A1.0x-1.9%N/A8.8%0.00%
    CareDx Inc (CDNA)$4.09B48.2x6.4x25.9%N/A39.3%0.00%
    OnKure Therapeutics, Inc. (OKUR)$108.33MN/AN/A0.0%N/A0.0%0.00%
    Veracyte Inc (VCYT)$1.96B13.3x3.3x21.8%8.2%15.1%0.00%
    Opko Health Inc (OPK)$1.25BN/A2.4x-22.6%-6.2%15.9%0.00%
    Coherus BioSciences Inc (CHRS)$81.21MN/A1.5x-253.4%-144.8%23.4%0.00%
    Coya Therapeutics, Inc. Common Stock (COYA)$73.42MN/A15.0x0.0%N/A-93.4%0.00%
    MDxHealth SA (MDXH)$13.75MN/AN/A-38.3%-40.5%-17.2%0.00%
    Peer median$77.32M30.8x2.4x-0.9%-23.3%7.6%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Insight Molecular Diagnostics, ranked by how closely their business, size, sector and industry match. The largest groups, 6 each of the 12, are in Biotechnology and Diagnostics & Research.

    CompanyAboutPeers
    Precipio Inc (PRPO)Diagnostics & Research
    Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market.
    PRPO competitors
    Exagen Inc (XGN)Diagnostics & Research
    Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name...
    XGN competitors
    Cardiff Oncology Inc (CRDF)Biotechnology
    Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer.
    CRDF competitors
    Oncolytics Biotech Inc (ONCY)Biotechnology
    Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer.
    ONCY competitors
    Champions Oncology Inc (CSBR)Biotechnology
    Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States.
    CSBR competitors
    CareDx Inc (CDNA)Diagnostics & Research
    CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally.
    CDNA competitors
    OnKure Therapeutics, Inc. (OKUR)Biotechnology
    OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer.
    OKUR competitors
    Veracyte Inc (VCYT)Diagnostics & Research
    Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
    VCYT competitors
    Opko Health Inc (OPK)Diagnostics & Research
    OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico...
    OPK competitors
    Coherus BioSciences Inc (CHRS)Biotechnology
    Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States.
    CHRS competitors
    Coya Therapeutics, Inc. Common Stock (COYA)Biotechnology
    Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs).
    COYA competitors
    MDxHealth SA (MDXH)Diagnostics & Research
    MDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers.
    MDXH competitors

    Frequently Asked Questions About IMDX

    Who are Insight Molecular Diagnostics' main competitors?

    The companies most similar to Insight Molecular Diagnostics include Precipio (PRPO), Exagen (XGN), Cardiff Oncology (CRDF), Oncolytics Biotech (ONCY) and Champions Oncology (CSBR), listed from the closest match.

    Who is Insight Molecular Diagnostics' biggest competitor?

    CareDx (CDNA) is the largest of the similar companies at $4.09B; Precipio (PRPO) is the closest match by business profile, size, sector and industry.

    How does IMDX stock compare with its competitors?

    IMDX's P/S is 40.9x against a peer median of 2.4x; its net margin is 0.0% against a peer median of -0.9%.

    Which of Insight Molecular Diagnostics' competitors pays a higher dividend?

    Insight Molecular Diagnostics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Insight Molecular Diagnostics bigger than its competitors?

    No. Insight Molecular Diagnostics is 8th by market cap among the 13 companies on this page; the largest is CareDx (CDNA) at $4.09B.